Product Code: SR112023A2814
Abstract
The global facial injectables market size reached US$ 7.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.5% during 2022-2028.
Facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin. These injectables are generally made using collagen, hyaluronic acid and calcium hydroxylapatite that help restore the elasticity of the skin. They are used to reduce wrinkles, augment lips, enhance shallow contours and raise depressed scars. Currently, facial injectables are gaining traction worldwide as they are safe, cost-effective and require minimal downtime.
As collagen production and formation of fat under the skin decline with age, the skin becomes more susceptible to wrinkles and sagging. This, in confluence with the growing geriatric population and the desire to retain a young and healthy skin, represents one of the key factors bolstering the market growth. Apart from this, the escalating demand for minimally invasive surgeries, coupled with the rising trend of medical and cosmetic tourism, is contributing to the market growth. Moreover, as excessive sun exposure leads to tissue breakdown of the skin, the demand for facial injectables is escalating among outgoing individuals. Furthermore, inflating disposable incomes, the rising influence of social media, and the growing number of professional practitioners and users willing to try organic and biodegradable materials are some of the other factors influencing the market positively. Besides this, the key players are also offering customized facial injectables to provide a personalized experience to users, which, in turn, is anticipated to create a positive outlook for the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global facial injectables market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, application type, application and end user.
Breakup by Product Type:
Collagen
Hyaluronic Acid (HA)
Botulinum Toxin Type A
Calcium Hydroxylapatite (CaHA)
Polymethylmethacrylate Beads (PMMA Microspheres)
Poly-L-Lactic Acid (PLLA)
Others
Breakup by Application Type:
Aesthetics
Therapeutics
Breakup by Application:
Facial Line Correction
Lip Augmentation
Face Lift
Acne Scar Treatment
Others
Breakup by End User:
Hospitals
Dermatology Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc.
Key Questions Answered in This Report
- 1. What is the global facial injectables market growth?
- 2. What are the global facial injectables market drivers?
- 3. What are the key industry trends in the global facial injectables market?
- 4. What is the impact of COVID-19 on the global facial injectables market?
- 5. What is the global facial injectables market breakup by product type?
- 6. What is the global facial injectables market breakup by application type?
- 7. What is the global voltage regulators market breakup by end user?
- 8. What are the major regions in the global facial injectables market?
- 9. Who are the key companies/players in the global facial injectables market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Facial Injectables Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Collagen
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Hyaluronic Acid (HA)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Botulinum Toxin Type A
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Calcium Hydroxylapatite (CaHA)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Polymethylmethacrylate Beads (PMMA Microspheres)
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Poly-L-Lactic Acid (PLLA)
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Application Type
- 7.1 Aesthetics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Therapeutics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Application
- 8.1 Facial Line Correction
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Lip Augmentation
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Face Lift
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Acne Scar Treatment
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Dermatology Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Allergan Plc
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Anika Therapeutics Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 SWOT Analysis
- 15.3.3 Bloomage BioTechnology
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Johnson & Johnson
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Galderma Pharma S.A.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 SWOT Analysis
- 15.3.6 Integra LifeSciences
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Ipsen (Mayroy SA)
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Medytox Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.9 Merz Holding GmbH & Co. KG
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.10 Prollenium Medical Technologies Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.11 Sanofi
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 SciVision Biotech Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.13 Sinclair Pharma (Huadong Medicine Co. Ltd.)
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.14 Suneva Medical Inc.
- 15.3.14.1 Company Overview
- 15.3.14.2 Product Portfolio
- 15.3.15 Bausch Health Companies Inc.
- 15.3.15.1 Company Overview
- 15.3.15.2 Product Portfolio
- 15.3.15.3 Financials
- 15.3.15.4 SWOT Analysis